Daniel Laskowitz, M.D., M.H.S.

Vice Chair and Professor of Neurology, Neurobiology, and Anesthesiology, Duke University Medical Center
Director of Neuroscience Medicine, Duke Clinical Research Institute
Director, Duke Neurovascular Laboratories 

Dr. Laskowitz has remained active in both laboratory-based and clinical research. He received his M.D. from Duke University School of Medicine in 2001, neurology residency training at the University of Pennsylvania, and his master of health science in clinical research in 2003. He attends on the stroke service and the Neurosciences Intensive Care Unit, and his perspective on drug development is shaped by the compelling unmet needs in the care of patients with acute and chronic brain injury. His research focus is on the role of genetic influences on neuroinflammatory responses, secondary neuronal injury and recovery from brain injury. Many of these cellular processes are common to both acute brain injury and chronic neurodegenerative disease, and preclinical results are translated to clinically relevant small animal models, with the ultimate goal of exploring new therapeutic interventions in the clinical setting of cerebrovascular disease, closed head injury and post-traumatic neurodegeneration.

Dr. Laskowitz has been involved with several translational trials evaluating new therapies in stroke and acute brain injury. His translational research also focuses on the use of biomarkers, both to investigate cellular mechanisms of post-traumatic neurodegeneration and to provide diagnostic and clinical information in the setting of ischemic and traumatic brain injury. He is a fellow of the American Heart Association and American Neurological Association, and has authored and co-authored more than 150 peer-reviewed articles.

Funded Research

Project Description Researchers Funding
The APOE Mimetic Therapeutic Peptide CN-105 Attenuates AD Pathology and Improves Functional Outcomes in a Murine Model of Alzheimer’s Disease

Increasing evidence suggests that brain inflammation plays an important role in mediating progression of Alzheimer’s disease (AD). In particular, it has been established that apolipoprotein E (APOE) plays a critical role in mediating neuroinflammation and disease pathology. We have developed specific APOE-based peptides that are rationally derived from the receptor-binding region of this protein, and we have demonstrated that these compounds are well tolerated, cross the blood-brain barrier, and reduce brain inflammation in preclinical models of AD and acute brain injury.